Literature DB >> 7437344

Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.

B G Durie, S E Salmon, G R Mundy.   

Abstract

Measurements of total body myeloma cell number and osteoclast activating factor (OAF) production by bone marrow myeloma cells in vitro were made in 33 patients with plasma cell myeloma. There was a highly significant correlation (P < 0.001) between the amount of OAF produced by bone marrow myeloma cells and the extent of skeletal destruction. Serial studies indicated reduction of OAF production with remission induction and high OAF production at the time of relapse with new bone destruction. Although hypercalcaemia occurred only in patients with the most extensive bone lesions, there was no direct relationship between OAF production and the serum calcium concentration. These data suggest that measurement of OAF production in multiple myeloma may predict those patients at risk for development of extensive skeletal destruction due to this neoplasm.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7437344     DOI: 10.1111/j.1365-2141.1981.tb02758.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Imaginological characterization of multiple myeloma lesions of the jaws through cone-beam computed tomography.

Authors:  Thaiza Gonçalves Rocha; Édila Figuerêdo Feitosa; Ângelo Maiolino; Roberto José Pessoa de Magalhães Filho; Fábio Ribeiro Guedes; Sandra Regina Torres; Maria Augusta Visconti
Journal:  Oral Radiol       Date:  2019-06-19       Impact factor: 1.852

2.  Tumor products and the hypercalcemia of malignancy.

Authors:  G R Mundy; K J Ibbotson; S M D'Souza
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

3.  Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

Authors:  R Bataille; D Chappard; C Marcelli; P Dessauw; P Baldet; J Sany; C Alexandre
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 4.  Hypercalcemia of malignancy revisited.

Authors:  G R Mundy
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

5.  Differentiation of plasma cell infiltrates in the bone marrow. A clinicopathological study on 80 patients including immunohistochemistry and morphometry.

Authors:  J Thiele; B Arenz; H Klein; M Vierbuchen; R Zankovich; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

6.  Canine lymphosarcoma: a model for study of the hypercalcemia of cancer.

Authors:  H Heath; R E Weller; G R Mundy
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

7.  Carcinomatous osteodysplasia.

Authors:  R Burkhardt; B Frisch; R Schlag; W Sommerfeld
Journal:  Skeletal Radiol       Date:  1982       Impact factor: 2.199

8.  Humoral hypercalcemia of malignancy. Release of a prostaglandin-stimulating bone-resorbing factor in vitro by human transitional-cell carcinoma cells.

Authors:  F R Bringhurst; B E Bierer; F Godeau; N Neyhard; V Varner; G V Segre
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

9.  Association between diffuse idiopathic skeletal hyperostosis and multiple myeloma.

Authors:  P N Scutellari; C Orzincolo; G Castaldi
Journal:  Skeletal Radiol       Date:  1995-10       Impact factor: 2.199

10.  A model for malignancy-associated humoral hypercalcemia.

Authors:  E C Abramson; L J Kukla; D H Shevrin; T E Lad; W P McGuire; S C Kukreja
Journal:  Calcif Tissue Int       Date:  1984-09       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.